Lineage Therap (LCTX) Stock Statistics & Valuation Metrics

Lineage Therap has a market cap or net worth of $283.16M. The enterprise value is $165.80M.

Lineage Therap has 228,356,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lineage Therap’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -21.43%.

The current PE Ratio of Lineage Therap is ―. Lineage Therap’s PEG ratio is ―.

In the last 12 months, Lineage Therap had revenue of 9.50M and earned -18.61M in profits. Earnings per share was -0.09.

In the last 12 months, operating cash flow was -22.56M and capital expenditures -388.00K, giving a free cash flow of -22.85M billion.

Lineage Therap pays an annual dividend of ―, resulting in a dividend yield of ―

Lineage Therap upcoming earnings date is Nov 5, 2025, After Close (Confirmed).

Lineage Therap as a current ratio of 3.65, with Debt / Equity ratio of 4.57%

In the past 12 months, Lineage Therap has paid 27.00K in taxes.

Lineage Therap EV to EBITDA ratio is -2.75, with an EV/FCF ratio of -2.42.

Lineage Therap has $42.29M in cash and marketable securities with $2.15M in debt, giving a net cash position of -$40.13M billion.

Gross margin is 72.58%, with operating margin of -226.11%, and net profit margin of -195.90%.

The average price target for Lineage Therap is $4.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy